Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-04-2006 | Original article

Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours

Authors: Winfried Brenner, Reinhard E. Friedrich, Karim A. Gawad, Christian Hagel, Andreas von Deimling, Maike de Wit, Ralph Buchert, Malte Clausen, Victor F. Mautner

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2006

Abstract

Purpose

In patients with neurofibromatosis type-1 (NF1) and malignant peripheral nerve sheath tumours (MPNSTs), survival rates are low and time to death is often less than 2 years. However, there are patients with a more favourable prognosis who develop metastases rather late or not at all. Since histopathology and tumour grading are not well correlated with prognosis, we aimed to evaluate the potential of ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) for prediction of patient outcome in MPNST.

Methods

FDG PET was performed in 16 patients with NF1 and MPNSTs. Standardised uptake values (SUVs) were calculated for each tumour and correlated to tumour grade and patient outcome in terms of survival or death.

Results

Three patients with tumour grade II had an SUV <3. None of these patients developed metastases or died during a follow-up of 41–62 months. Thirteen patients with tumour grades II and III had an SUV >3. Only one of these patients is still alive after 20 months; the remaining 12 died within 4–33 months. SUV predicted long-term survival with an accuracy of 94%, compared with 69% for tumour grade. In Kaplan-Meier survival analysis, patients with an SUV >3 had a significantly shorter mean survival time, 13 months, than patients with an SUV <3, in whom the mean survival time was 52 months. Tumour grading did not reveal differences in survival time (15 vs 12 months).

Conclusion

Tumour SUV obtained by FDG PET was a significant parameter for prediction of survival in NF1 patients with MPNSTs while histopathological tumour grading did not predict outcome.

Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989;26:704–11PubMedCrossRef

Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 2005;141:71–4PubMedCrossRef

Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002;62:1573–7PubMed

Mautner VF, Hartmann M, Kluwe L, Friedrich RE, Fünsterer C. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology (in press)

McGaughran JM, Harris DI, Donnai D, Teare D, MacLeod R, Westerbeek R, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999;36:197–203PubMed

Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001;68:1110–8PubMedCrossRef

Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006–21PubMedCrossRef

Stark AM, Buhl R, Hugo HH, Mehdorn HM. Malignant peripheral nerve sheath tumours—report of 8 cases and review of the literature. Acta Neurochir (Wien) 2001;143:357–63; discussion 363–4CrossRef

Mautner VF, Friedrich RE, von Deimling A, Hagel C, Korf B, Knofel MT, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology 2003;45:618–25PubMedCrossRef

10.

Fletcher CD. The histological features of local recurrences of soft tissue sarcomas. Pathologe 1994;15:196–200PubMedCrossRef

11.

Eary JF, O’Sullivan F, Powitan Y, Chandhury KR, Vernon C, Bruckner JD, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149–54PubMedCrossRef

12.

Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004;31:189–95PubMedCrossRef

13.

Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914–26PubMedCrossRef

14.

Solomon SB, Semih Dogan A, Nicol TL, Campbell JN, Pomper MG. Positron emission tomography in the detection and management of sarcomatous transformation in neurofibromatosis. Clin Nucl Med 2001;26:525–8PubMedCrossRef

15.

Chander S, Westphal SM, Zak IT, Bloom DA, Zingas AP, Joyrich RN, et al. Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med 2004;29:415–8PubMedCrossRef

16.

Otsuka H, Graham MM, Kubo A, Nishitani H. FDG-PET/CT findings of sarcomatous transformation in neurofibromatosis: a case report. Ann Nucl Med 2005;19:55–8PubMed

17.

Ferner RE, Lucas JD, O’Doherty MJ, Hughes RA, Smith MA, Cronin BF, et al. Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2000;68:353–7PubMedCrossRef

18.

Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer G, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 2003;29:536–41PubMedCrossRef

19.

Higashi K, Ueda Y, Ayabe K, Sakurai A, Seki H, Nambu Y, et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707–14PubMedCrossRef

20.

Dhital K, Saunders CA, Seed PT, O’Doherty MJ, Dussek J. [¹⁸F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18:425–8PubMedCrossRef

21.

Allal AS, Dulguerov P, Allaoua M, Haenggeli CA, El-Ghazi el A, Lehmann W, et al. Standardized uptake value of 2-[¹⁸F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002;20:1398–404PubMedCrossRef

Title: Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours
Authors: Winfried Brenner
Reinhard E. Friedrich
Karim A. Gawad
Christian Hagel
Andreas von Deimling
Maike de Wit
Ralph Buchert
Malte Clausen
Victor F. Mautner
Publication date: 01-04-2006
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-005-0030-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2006

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033

Molecular imaging of cell transplantation in Parkinson’s disease

Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes

The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma

PET/MRI depicts the exact location of meniscal tear associated with synovitis

Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom